Catalyst Brief

← Calendar

Readoutin 45d

Amgen — Maridebart Cafraglutide

Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.

Date
Jan 2027
Type
Readout
Indication
Obesity

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Amgen

  1. Apr2027